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Abstract: Anthraquinones are an important class of naturally occurring biologically active 
compounds. In this study, anthraquinone derivative 1,3-dihydroxy-9,10-anthraquinone-2- carboxylic 
acid (DHAQC) (2) was synthesized with 32% yield through the Friedel–Crafts condensa tion reac-
tion. The mechanisms of cytotoxicity of DHAQC (2) in human breast cancer MCF-7 cells were 
further investigated. Results from the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay showed that DHAQC (2) exhibited potential cytotoxicity and selectivity 
in the MCF-7 cell line, comparable with the naturally occurring anthraquinone damnacanthal. 
DHAQC (2) showed a slightly higher IC
50
 (inhibitory concentration with 50% cell viability) 
value in the MCF-7 cell line compared to damnacanthal, but it is more selective in terms of 
the ratio of IC
50
 on MCF-7 cells and normal MCF-10A cells. (selective index for DHAQC (2) 
was 2.3 and 1.7 for damnacanthal). The flow cytometry cell cycle analysis on the MCF-7 
cell line treated with the IC
50
 dose of DHAQC (2) for 48 hours showed that DHAQC (2) 
arrested MCF-7 cell line at the G2/M phase in association with an inhibited expression of PLK1 
genes. Western blot analysis also indicated that the DHAQC (2) increased BAX, p53, and cytochrome 
c levels in MCF-7 cells, which subsequently activated apoptosis as observed in annexin V/propidium 
iodide and cell cycle analyses. These results indicate that DHAQC (2) is a synthetic, cytotoxic, 
and selective anthraquinone, which is less toxic than the natural product damnacanthal, and which 
demonstrates potential in the induction of apoptosis in the breast cancer MCF-7 cell line.
Keywords: cytotoxic, selective index, cell cycle
Introduction
Cancer is one of the most major health problems, according to any frame of reference, 
and, unfortunately, is not likely to lose that qualification any time soon. The breast is 
one of the four major cancer sites, and, of all cancers, breast cancer has the highest 
incidence rate and is the second highest cause of death in females.1 Thus, research in 
medicinal chemistry has been focused on the discovery of novel anticancer compounds, 
including natural compounds that can specifically target cancer cells and minimize the 
possible side effects on normal cells.2 Anthraquinones are potential natural anticancer 
compounds that can be isolated from Damnacanthus and Morinda spp. Among the 
natural anthraquinones, damnacanthal has been shown to possess potential cytotoxic, 
immunomodulatory,3 and anticancer activities.4 These cytotoxic and apoptotic activi-
ties against breast cancer cell lines were found to be regulated by damnacanthal via 
activation of p53 and p21 genes.5 Other naturally occurring anthraquinones have also 
been shown to exhibit similar anti-inflammatory, antibiotic, antiviral, and antineoplastic 
activities.6–8 However, due to the lack of accessibility, the time and cost of preparation, 
and the limited quantity of naturally occurring anthraquinones, chemically synthesized 
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
984
Yeap et al
compounds have garnered a great deal of attention as a 
means of complementing the natural isolated compounds in 
anticancer drug discovery.9 Based on this connection, we syn-
thesized the compound 1,3-dihydroxy-9,10-anthraquinone-
2-carboxylic acid (DHAQC) (2) by Jones oxidation10 similar 
to the previously synthesized compound, 2-hydroxymethyl-
1,3-dimethoxy-9,10-anthraquinone (1).
One of the major obstacles in anticancer compound 
discovery is that the candidate compounds could have 
nonspecific toxicity against both cancerous and normal 
cells.11 Thus, identification of a novel compound with high 
selectivity against cancerous cells rather than normal cells 
is one of the major objectives of this type of study. The cur-
rent study aimed to evaluate and compare the selectivity of 
DHAQC (2) to damnacanthal on cancerous and normal cell 
lines. Moreover, the cell cycle arrest and apoptotic effects of 
DHAQC (2) on MCF-7 cells was also evaluated by quantita-
tive polymerase chain reaction (PCR), Western blot, and flow 
cytometry analysis.
Materials and methods
synthesis of DhaQc (2)
Damnacanthal was synthesized according to the methods 
of Akhtar et al.12 Compound (1) (2-hydroxymethyl-1,3-
 dimethoxy-9,10-anthraquinone) was synthesized as described 
in our previous publication.12 Briefly, the phthalic anhydride 
and 1,3-dihydroxy-2-methylbenzene were mixed in a molten 
mixture of AlCl
3
/NaCl. Then, the product was acetylated with 
acetic anhydride and potassium carbonate. Next, the product 
underwent methylation with K
2
CO
3
/(CH
3
)
2
SO
4
, which was 
further brominated with Wohl-Ziegler’s reaction. Finally, 
the product was hydrolyzed in acetic acid and water (8:2) 
to yield compound (1). For the synthesis of compound (2), 
DHAQC (2), compound (1) (500 mg, 1.7 mmol) was dis-
solved in 30 mL of acetone in a round bottle flask equipped 
with a CaCl
2
 drying tube. The reaction mixture was stirred at 
0°C–5°C in an ice bath. Jones reagent was prepared by mixing 
CrO
3
 + H
2
SO
4
 at 0°C in acetone. After 2 hours of storage in a 
refrigerator, 5 mL of the Jones reagent was diluted with water 
and added slowly under nitrogen atmosphere until the yellow 
solution turned greenish. The product was treated with 5% 
solution of sodium bisulfite, extracted with ethyl acetate, and 
purified by column chromatography. The compound DHAQC 
(2) was analyzed by electron ionization mass spectrometry 
(EI-MS), infrared (IR), and nuclear magnetic resonance 
spectroscopic (NMR) techniques. Compound (2) was 
obtained as a yellow-green amorphous powder and purified 
by column chromatography. The yield was 32.0%. IR (cm-1) 
in KBr disk: 3450-, 3230 (OH), 2973 (CH), 1646 (H-C=O), 
1670 (non-chelated C=O), 1466 (C=C, aromatic), 1244, 
1262, 1230, 1132, 710. 1H-NMR (500 MHz, acetone-d
6
): 
δ 12.21 (s, OH), 8.22 (d, 1H, J=7.5 Hz, H-8), 8.09 (d, 1H, 
J=7.5 Hz, H-5), 7.75–7.72 (m, 2H, H-6, and H-7), 7.70 (s, 
1H, H-4), MS m/z (relative intensity): 284.20 (M+, 242), 
281 (45), 226 (56), 254 (79), 206 (7), 196 (24), 180 (57), 
77, 65, 54. 
cell culture
Human erythromyeloblastoid leukemia K562 cells, 
estrogen-dependent breast cancer MCF-7 cells, estrogen-
independent breast cancer MDA-MB-231 cells, and normal 
breast MCF-10A cells were purchased from American Type 
Culture Collection ([ATCC] Manassas, VA, USA). K562 
and MCF-7 cells were cultured in Roswell Park Memorial 
Institute (RPMI)-1640 (Sigma-Aldrich Co, St Louis, MO, 
USA) and supplemented with 10% fetal bovine serum (FBS) 
(GE Healthcare, Little Chalfont, UK), while MDA-MB-231 
cells were cultured in  Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Sigma-Aldrich Co) supplemented with 10% FBS. 
MCF-10A cells were cultured in DMEM/F-12 (Sigma-Al-
drich Co)  supplemented with 10% FBS, hydrocortisone (0.5 
µg/mL), insulin (10 µg/mL), and human epidermal growth 
factor (20 ng/mL) (Sigma-Aldrich Co). All cell lines were 
kept in a 37°C incubator with 5% CO
2
.
3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)  
cell viability assay
MCF-7, MDA-MB-231, and MCF-10A cells were seeded 
in 96-well plates (0.8×105 cells/mL) and cultured overnight. 
Then, starting at 30 µg/mL, serial 1:1 dilutions of the exam-
ined compounds were added to triplicate wells on the seeded 
plates. The nonadherent K562 cells were loaded (0.8×105 
cells/mL) on the 96-well plate, which contained the appro-
priate dilutions of compounds. All plates were incubated for 
48 hours at 37°C, 5% CO
2
. After the incubation period, 20 µL 
of MTT (5 mg/mL) solution (Sigma-Aldrich Co) was added 
to all wells and incubated in darkness for 3 hours. Then, 
170 µL of solution was discarded and 20 µL of dimethyl 
sulfoxide (DMSO) was added to each well to solubilize the 
purple crystals. The plates were read using a microplate 
reader at 570 nm (BioTek Instruments, Inc., Winooski, VT, 
USA). IC
50
 (inhibitory concentration with 50% cell viabil-
ity) values, indicating the concentration of DHAQC (2) or 
damnacanthal that inhibited 50% of cell viability compared 
to untreated control, were obtained, and selective index was 
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calculated by dividing the IC
50
 value of MCF-10A cells by 
the IC
50
 value of MCF-7 or MDA-MB-231 cells. 
cell preparation
MCF-7 cells were seeded overnight and treated with the IC
50
 
value of DHAQC (2) for 24 hours for quantitative real-time 
PCR (qRT-PCR) and with IC
25
 (inhibitory concentration 
that inhibits 25% of cell viability) (3.50 µg/mL) and IC
50
 
(7.20 µg/mL) of DHAQC (2) for 48 hours for flow cytom-
etry, Western blot, and caspase-9 analysis. Untreated control 
cells were prepared simultaneously. After the treatment 
period, cells were harvested, washed, and subjected to the 
following assays.
Flow cytometry cell cycle Pi (propidium iodide) assay
Treated and untreated MCF-7 cells were stained with BD 
CycletestTM Plus DNA reagent kit (BD, Franklin Lakes, NJ, 
USA) according to the manufacturer’s protocol. The cell 
cycle phase was analyzed using BD CellQuest Pro software 
by FACSCalibur™ (BD, Franklin Lakes, NJ, USA).
Flow cytometry annexin V/Pi assay
Treated and untreated MCF-7 cells were mixed with 100 
µL of 1× binding buffer. Then, 5 µL of annexin V and PI, 
each from the Annexin V-FITC apoptosis detection kit (BD 
Biosciences, San Jose, CA, USA), were added to the cells 
and incubated for 15 minutes. Afterwards, stained cells were 
washed and mixed with 500 µL of 1×  binding buffer, and the 
apoptosis of the cells was analyzed using BD CellQuest Pro 
software by FACSCalibur.
qrT-Pcr assay
RNA from the treated and untreated MCF-7 cells was 
extracted using the RNeasy Plus Mini Kit (Qiagen NV, Venlo, 
the Netherlands) according to the manufacturer’s protocol. The 
RNA quality was quantified using a NanoDrop spectrophotom-
eter (Thermo Fisher Scientific, Waltham, MA, USA). The RNA 
was converted to complementary (c)DNA using an iScriptTM 
cDNA synthesis kit (Bio-Rad Laboratories Inc., Hercules, CA, 
USA). Expression of p21, PLK1, and FOXM1 were evaluated 
by qRT-PCR with an SYBR® Select Master Mix (Thermo 
Fisher Scientific, Waltham, MA, USA) on an iQ-5 Real Time 
PCR (Bio-Rad Laboratories Inc.) using the primers as stated in 
Table 1 and the following PCR conditions: one cycle of 50°C 
for 2 minutes for UDG (uracil-DNA glycosylase) activation; 
one cycle of 95°C for 2 minutes for DNA polymerase activa-
tion; 40 cycles of 95°C for 2 seconds for denature; and 60°C 
for 30 seconds for annealing and extension. Standard curves 
for housekeeping genes (β-actin, 18srRNA, and GAPDH) and 
target genes (p21, PLK1, and FOXM1) were generated from 
the amplification of the serially diluted RNA samples isolated 
from the control MCF-7 cell line to optimize the assay. Each 
of the, treated and untreated samples were run in triplicate and 
non-template control was included. Normalization of reference 
genes was done using geNorm.13
Western blot analysis
Protein was extracted from IC
25
 and IC
50
 DHAQC (2)-treated 
and untreated control cells using radioimmunoprecipitation 
assay buffer, and the protein concentration was determined 
using Bradford protein assay (Thermo Fisher Scientific). The 
cell homogenates were electrophoresed by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA), transferred 
onto nitrocellulose membrane, blocked with Tris-buffered 
saline–Tween buffer containing 5% skimmed milk powder 
for 1 hour, and incubated with primary antibodies (anti-p53, 
anti-BAX, anti-Bcl-2, anti-cytochrome c, and anti-β-actin at 
dilution 1:1000) (Abcam plc, Cambridge, UK) for another 
hour. Then, membranes were washed and incubated with 
the anti-rabbit secondary antibodies-conjugated with alka-
line phosphatase (1:5000 dilution) for 1 hours, followed by 
washing with Tris-buffered saline–Tween buffer, and finally 
visualized by chemiluminescence with CDP-Star® reagent 
(NEB [UK], Hitchin, UK) using a BioSpectrum® system 
(UVP, Upland, CA, USA). The size of the targeted proteins 
was determined by protein marker (PageRuler Prestained 
Protein Ladder; Thermo Fisher Scientific), and the density 
results obtained from this targeted protein were analyzed using 
VisionWorks®LS analysis software (Version 7.1 RC3.54; 
UVP) by normalizing against β-actin.
Table 1 Quantitative real-time polymerase chain reaction primers 
designed for quantification of FOXM1, WEE1, p21, and PLK1 genes
Accession 
number
Gene Sequence
nM_001220778.1 p21 F: 5-TgTccgTcagaacccaTgc-3 
r: 5-aaagTcgaagTTccaTcgcTc-3
nM_005030.3 PLK1 F: 5-ccTgcaccgaaaccgagTTaT-3 
r: 5-ccgTcaTaTTcgacTTTggTTgc-3
nM_001243089.1 FOXM1 F: 5-aTacgTggaTTgaggaccacT-3 
r: 5-TccaaTgTcaagTagcggTTg-3
nM_001101.3 ACTB F: 5′-agagcTacgagcTgccTgac-3′ 
r: 5′-agcacTgTgTTggcgTacag-3′
hQ387008.1 18srRNA F: 5-gTaacccgTTgaaccccaTT-3 
r: 5-ccaTccaaTcggTagTagcg-3
nM_002046.4 GAPDH F: 5-ggaTTTggTcgTaTTgggc-3 
r: 5-TggaagaTggTgaTgggaTT-3
Note: ACTB, 18srRNA, and GAPDH were housekeeping genes used for normalization 
of the target genes.
Abbreviations: F, forward; r, reverse.
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Caspase-9 fluorescence assay and viability  
in the presence of general caspase inhibitor
MCF-7 cells were pretreated with or without cell perme-
able general caspase inhibitor (Z-VAD-FMK) (Promega 
Corporation, Fitchburg, WI, USA) at 10 µM before treatment 
with IC
25
 and IC
50
 of DHAQC (2) for 48 hours. After the treat-
ment period, viability of DHAQC (2)-treated MCF-7 cells with 
or without Z-VAD-FMK was quantified using MTT assay as 
described above. Then, protein was extracted from IC
25
 and IC
50
 
DHAQC (2)-treated and untreated control cells with or without 
Z-VAD-FMK using radioimmunoprecipitation assay buffer, 
and the protein concentration was determined using Bradford 
protein assay. Levels of activated caspase-9 were detected using 
CaspGLOW Red Active Caspase-9 Staining Kit (BioVision, 
Inc., Milpitas, CA, USA) according to the manufacturer’s 
protocol. The fluorescence intensity in DHAQC (2)-treated 
and untreated MCF-7 cells was measured at excitation (Ex)/
emission (Em) =540/570 nm using a microplate fluorometer 
(Arzoskan Flash; Thermo Fisher Scientific).
statistical analysis
Data were presented as mean ± standard deviation from three 
experiments in three different biological replicates, and the 
significance (P,0.05) was evaluated by one-way analysis 
of variance (ANOVA) with Duncan test as post hoc analysis 
using SPSS software (v 14; SPSS Inc., Chicago, IL, USA).
Results and discussion
Chemical modifications in the side chain are one common 
approach in drug discovery for improving the therapeutic 
potential of a certain compound. Our main interest was to 
improve the yield of damnacanthal using different kinds of 
oxidizing agents, such as AgO/HNO
3
, Vilsmeier reagent, and 
Lewis acid.14 None of the methods gave a reasonable yield and 
most gave oxidative demethylated products.14 However, the 
oxidation approach of a previously synthesized compound, 
2-hydroxymethyl-1,3-dimethoxy-9,10-anthraquinone (1),12 
with Jones reagents10 resulted in a 32% yield of DHAQC (2) 
(Figure 1).
Both damnacanthal and DHAQC (2) contain the 
anthraquinone planer basic skeleton, which is the major 
contributor to the cytotoxicity properties. The planar tricyclic 
structure of anthraquinone is essential for cytotoxic activi-
ties and has been widely investigated for cancer therapy.15 
Anthraquinone derivatives such as doxorubicin, daunorubi-
cin, and carminomycin are highly effective in the treatment 
of tumors.16 Cytotoxicity of DHAQC (2) on K562, MCF-7, 
and MCF-10A cell lines was evaluated using the MTT assay, 
and IC
50
 value of these cell lines after 48 hours of treatment 
were obtained (Table 2). The selectivity of DHAQC (2) 
and damnacanthal on normal and cancerous cell lines was 
calculated by dividing the IC
50
 on normal MCF-10A cells 
by that of either estrogen-dependent MCF-7 or estrogen-
independent MDA-MB-231 cells. Both DHAQC (2) and 
damnacanthal showed the highest cytotoxicity against MCF-7 
compared to the other cell lines. Further, the IC
50
 values of 
DHAQC (2) and damnacanthal in MCF-7 and K562 were 
lower compared to the precursor, compound (1) with IC
50
 
values of 12.80 and 14.00 µg/mL, respectively.12 Previously, 
we demonstrated the contribution of methoxy, CHO groups, 
and OH group to the cytotoxicity of anthraquinones against 
tested cancerous cell lines.12 DHAQC (2) possesses two OH 
groups and one carboxylic acid (COOH) group, which gives 
it a greater hydrophilic character compared to damnacanthal. 
The presence of hydroxyl and acidic groups in DHAQC (2) 
increases the solubility and might facilitate absorption or 
diffusion across the cellular membrane, as revealed by the 
theoretical membrane-interaction quantitative structure–
activity relationship (MI-QSAR) studies of 188 drug-like 
compounds.17,18 The better selectivity of DHAQC (2) toward 
cancer cell lines is possibly a result of its hydrophilic charac-
ter, which might fulfill Lipinski’s rule of five and have drug-
like properties.19 Many drugs, for instance, mitoxantrone, 
possessing 1,4 hydroxyl groups have demonstrated potent 
antitumor activity and have been used widely in clinic since 
1980.20,21 Moreover, the hydrophilic property of DHAQC (2) 
O
O OCH3
OCH3
CH2OH0.25 mole% CrO3/+H
O
O OH
OH
COOH
2
1
Figure 1 synthesis of DhaQc (2) from 2-hydroxymethyl-1,3-dimethoxy-9, 
10-anthraquinone (1).
Abbreviation: DhaQc, 1,3-dihydroxy-9,10-anthraquinone-2-carboxylic acid.
Table 2 The ic50 values of DhaQc (2) and damnacanthal in 
K562, McF-7, MDa-MB-231, and McF-10a cell lines after 48 
hours of treatment
Cell line DHAQC (2) 
(μg/mL)
Damnacanthal 
(μg/mL)
K562 9.10±1.16 6.20±1.32
McF-7 7.20±1.00 4.30±0.67
MDa-MB-231 9.94±1.25 7.13±1.38
McF-10a 24.15±1.13 6.51±1.65
selective index of McF-10a/McF-7 3.35 1.51
selective index of McF-10a/MDa-
MB-231
2.43 0.91
Note: selective indexes on breast cancer cells were calculated based on ic50 of 
McF-10a normal cells versus McF-7 and MDa-MB-231 cells.
Abbreviations: DhaQc, 1,3-dihydroxy-9,10-anthraquinone-2-carboxylic acid; ic50, 
inhibitory concentration with 50% cell viability.
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may also be involved in it’s chelating with magnesium and 
zinc ions in DNA synthesis and the repair process.15 Added 
to this, the hydrophilicity or introduction of acidic groups 
increased the hydrophilicity of the rings and facile to bind 
with receptor. It is well known that the polycyclic (aromatic) 
structure of anthraquinone can intercalate with DNA in 
between base pairs, either covalently or  electrostatically. This 
DNA intercalation with anthraquinone compounds possibly 
inhibits the DNA replication in cancer cell lines.22 Previous 
research found that the position but not the total amount 
of hydroxyl in anthraquinone played an important role in 
determining its toxicity against normal and cancerous cell 
lines in vitro. Thus, modification of the hydroxyl group in 
DHAQC (2) might reduce its toxicity to normal cells while 
maintaining its apoptosis-inducing effect on cancer cells, 
thus leading to greater selectivity of DHAQC (2) compared 
to that of damnacanthal.23 As a result, the slight modification 
in natural compounds, as in DHAQC (2), could be useful for 
the development of new prototypes of anthraquinone-type 
cytotoxic agents.
Since DHAQC (2) showed the highest sensitivity and 
selectivity on hormone-dependent breast cancer MCF-7 
cells, further evaluation on cell cycle regulation, apoptosis, 
gene expression, and apoptosis-related protein levels were 
evaluated. The cell cycle regulation and apoptotic effects 
were evaluated using flow cytometry after 48 hours of 
 treatment. Many cytotoxic agents arrest the cell cycle 
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of cancerous cells at the S and G2/M phases, followed 
by the induction of  apoptosis.24 DHAQC (2) arrested 
MCF-7 at the S and G2/M phases (21.33%±1.74% and 
37.66%±4.11%, respectively) as compared to the control 
(11.76%±1.31% and 4.48%±%3.72%, respectively) 
after 48 hours of incubation. DHAQC (2) also induced 
20.48%±2.91% of the MCF-7 cell population to enter the 
subG0 phase, which indicated the occurrence of DNA 
fragmentation in the DHAQC (2)-treated cells. This result 
was further supported by the annexin V/PI apoptosis study, 
wherein DHAQC (2) was able to induce 16.36%±3.72% 
of cells to undergo late apoptosis and 29.35%±3.81% to 
undergo early apoptosis (Figure 2). These cell cycle and 
apoptosis results were similar to those of our previous study, 
wherein damnacanthal was found to induce G2/M arrest, 
DNA fragmentation, and apoptosis toward MCF-7 cells.5
Since cell cycle arrest was observed in DHAQC (2)-treated 
MCF-7 cells, expression of p21, PLK1, and FOXM1 genes 
involved in G2/M arrest was evaluated using qRT-PCR. PLK1 
is a key regulator of G2/M phase progression, while forkhead 
box M1 (FOXM1) is a direct binding partner of PLK1, FOXM1 
plays an important role in regulating the mitotic entry and 
expression of clusters of G2/M target genes.25 Downregulation 
of PLK1 and FOXM1 expression are always associated with 
G2/M arrest and apoptosis (Kim et al, 2012).26 On the other 
hand, upregulation of p21 was found to arrest the cell cycle 
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in the G2/M phase as reported in damnacanthal-treated 
MCF-7 cells.5 Based on the qRT-PCR results, DHAQC (2) 
was able to inhibit the expression of PLK1 significantly. 
Further, expression of p21 and FOXM1 were up- and down-
regulated, respectively, although it is not significant (Figure 3). 
 Depletion of PLK1 gene was also reported to subsequently 
induce apoptosis in cancer cells (Liu and Erikson, 2003).27 
Thus, significant PLK1 downregulation by DHAQC (2) con-
tributed to the G2/M arrest and apoptosis in MCF-7 cells as 
observed in the flow cytometry analysis.
Besides regulation of G2/M arrest-related genes, effects 
of DHAQC (2) on apoptosis-related proteins, including Bcl-2, 
BAX, p53, and cytochrome c, were also evaluated by Western 
blot analysis. After 48 hours of treatment, both IC
25
 and IC
50
 
of DHAQC (2) were able to enhance the levels of p53, BAX, 
and cytochrome c, but had no dose-dependent effect on Bcl-2 
(Figure 4). The ability of DHAQC (2), as an anthraquinone, to 
bind and chelate the DNA may contribute to enhancement of 
p53 levels.28 Furthermore, this DNA binding ability may be fur-
ther enhanced by the increased hydrophilic property of DHAQC 
(2). p53 is a tumor suppressor protein that plays an important 
role in regulating G2/M arrest and apoptosis via upregulation of 
p21, transcriptional target of p53, and multidomain proapoptotic 
protein BAX. BAX is essential for the onset of mitochondrial 
permeabilization and apoptosis via the intrinsic pathway. The 
balance between expression levels of antiapoptotic Bcl-2 and 
proapoptotic BAX is crucial for cell survival or death, wherein 
increase of the BAX/Bcl-2 ratio will activate the release of 
cytochrome c from mitochondria and subsequently activate the 
intrinsic apoptotic pathway.29 Induction of BAX increased the 
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BAX/Bcl-2 ratio, which subsequently enhanced the release of 
cytochrome c from the mitochondria (Figure 4) and increased 
the level of activated caspase-9 (Figure 5), which indicates 
the activation of the intrinsic apoptotic pathway.24 Similarly to 
another anthraquinone derivative, dantron,30 stimulation of acti-
vated caspase-9 and reduction of cell viability was suppressed 
in the presence of general caspase inhibitor Z-VAD-FMK. 
These results indicate that activation of caspase-9 is crucial for 
induction of apoptosis in MCF-7 by DHAQC (2). Furthermore, 
activation of p53 that induced G2/M arrest and the intrinsic 
apoptotic pathway was similar to the effects induced by dam-
nacanthal.5 Additionally, regulation of these apoptosis-related 
proteins was in a dose-dependent manner, wherein upregulation 
of BAX, p53, cytochrome c, and caspase-9 were found to be 
higher in MCF-7 cells treated with IC
50
 of DHAQC (2) than 
in those treated with IC
25
 of DHAQC (2). 
Conclusion
This study indicates that the production of DHAQC (2) 
warranted a better yield (32%) than the synthesis of 
 damnacanthal. The synthesized DHAQC (2) also possessed 
better selectivity against estrogen-dependent breast cancer 
MCF-7 cells compared to damnacanthal. The better selectiv-
ity of DHAQC (2) compared with damnacanthal may have 
resulted from the increase of hydrophilicity or introduction 
of acidic groups. Induction of cell death by DHAQC (2) was 
contributed by G2/M cell cycle arrest and the downregulation 
of the PLK1 gene induces the intrinsic pathway of apoptosis 
via upregulation of p53, BAX/Bcl-2 ratio, and release of 
cytochrome c (Figure 6).  Caspase inhibitor Z-VAD-FMK 
prevented the cell death induced by DHAQC (2) and inhib-
ited the increase of active caspase-9 levels, suggesting that 
caspase-9 might be involved in DHAQC (2)-induced apop-
tosis of MCF-7 cells. Besides cell cycle arrest and apoptosis, 
damnacanthal demonstrated other bioactivities, including 
inhibition of cell migration and invasion via inhibition of 
kinases.31 Thus, further evaluation and comparison of the 
mechanisms of in vitro and in vivo antitumor and antimeta-
static effects via inhibition of protein tyrosine kinase between 
DHAQC (2) and damnacanthal should be carried out.
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